Clinical trial
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
NCT00110357 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00110357 |
|---|---|
| Title | Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors |
| Official title | Phase I Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Refractory Solid Tumor |
| Intervention type | Drug |
| Interventions | Cetuximab + Irinotecan |
| Enrollment | 48 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | May 9, 2005 |
| Last update posted | Dec 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: